The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells

Leukemia

Volumn 26, Issue 12, 2012, Pages 2554-2557

  Johnson, A J ^a   Yeh, Y Y ^a   Smith, L L ^a   Wagner, A J ^a   Hessler, J ^a   Gupta, S ^a   Flynn, J ^a   Jones, J ^a   Zhang, X ^a   Bannerji, R ^b   Grever, M R ^a   Byrd, J C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CD40 LIGAND; CYTOKINE; DINACICLIB; INTERLEUKIN 4; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MCL 1;

APOPTOSIS; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; LETTER; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

BICYCLO COMPOUNDS, HETEROCYCLIC; CYCLIN-DEPENDENT KINASES; CYTOKINES; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTEIN KINASE INHIBITORS; PYRIDINIUM COMPOUNDS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84871236598     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.144     Document Type: Letter

References (11)

1. Grever MR, Lucas DM, Johnson AJ, Byrd JC. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20: 545-556.
2. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL et al. Flavo-piridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92: 3804-3816.
3. Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997; 90: 4307-4312.
4. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 393-397.
5. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009; 113: 2637-2645.
6. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27: 6012-6018.
7. Paruch K, Dwyer MP, Alvarez C, Brown C, Chan T-Y, Doll RJ et al. Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases. ACS Med Chem Lett 2010; 1: 204-208.
8. Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010; 9: 2344-2353.
9. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV et al. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009; 113: 5549-5557.
10. Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 2008; 111: 3190-3199.
11. Woyach JA, Lozanski G, Ruppert AS, Lozanski A, Blum KA, Jones JA et al. Outcome of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) treated with flavopiridol: Impact of Genomic Features. Leukemia 2012; 26: 1442-1444.